Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Cressey

Showing results (81-90 of 160) with videos related to

Pageof 16
Sort By:
The Pediatric Infectious Disease Journal|July 31, 2015
Efavirenz Concentrations and Probability of HIV Replication in ChildrenNontiya Homkham, Tim R Cressey, Naïm Bouazza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 12, 2018
Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIVDeborah Ford, Rebecca Turner, Anna Turkova, et al.
BMC Infectious Diseases|July 15, 2017
A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET studyTim R Cressey, Oraphan Siriprakaisil, Virat Klinbuayaem, et al.
Antimicrobial Agents and Chemotherapy|February 25, 2009
Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai womenTim R Cressey, Russell Van Dyke, Gonzague Jourdain, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir StudyTim R Cressey, Nicolas Salvadori, Helena Rabie, et al.
Clinical Pharmacokinetics|February 2, 2021
Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and RaltegravirXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 20, 2020
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarateTim R Cressey, Oraphan Siriprakaisil, Rachel W Kubiak, et al.
The Lancet. HIV|July 21, 2022
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studiesTom G Jacobs, Stef Schouwenburg, Martina Penazzato, et al.
The Lancet. HIV|January 31, 2024
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
Clinical Pharmacokinetics|May 27, 2020
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic ModelingXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
Pageof 16

Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
The Pediatric Infectious Disease Journal|July 31, 2015
Efavirenz Concentrations and Probability of HIV Replication in ChildrenNontiya Homkham, Tim R Cressey, Naïm Bouazza, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 12, 2018
Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIVDeborah Ford, Rebecca Turner, Anna Turkova, et al.
BMC Infectious Diseases|July 15, 2017
A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET studyTim R Cressey, Oraphan Siriprakaisil, Virat Klinbuayaem, et al.
Antimicrobial Agents and Chemotherapy|February 25, 2009
Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai womenTim R Cressey, Russell Van Dyke, Gonzague Jourdain, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Single Doses of Pediatric Dolutegravir Dispersible Tablets in Neonates Support Multidosing: PETITE-Dolutegravir StudyTim R Cressey, Nicolas Salvadori, Helena Rabie, et al.
Clinical Pharmacokinetics|February 2, 2021
Physiologically Based Pharmacokinetic Modeling Framework to Predict Neonatal Pharmacokinetics of Transplacentally Acquired Emtricitabine, Dolutegravir, and RaltegravirXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|June 20, 2020
Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarateTim R Cressey, Oraphan Siriprakaisil, Rachel W Kubiak, et al.
The Lancet. HIV|July 21, 2022
What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studiesTom G Jacobs, Stef Schouwenburg, Martina Penazzato, et al.
The Lancet. HIV|January 31, 2024
Paediatric abacavir-lamivudine fixed-dose dispersible tablets and ritonavir-boosted lopinavir granules in neonates exposed to HIV (PETITE study): an open-label, two-stage, single-arm, phase 1/2, pharmacokinetic and safety trialAdrie Bekker, Nicolas Salvadori, Helena Rabie, et al.
Clinical Pharmacokinetics|May 27, 2020
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic ModelingXiaomei I Liu, Jeremiah D Momper, Natella Y Rakhmanina, et al.
Pageof 16